Two Pharma Giants Who'd Never Met | Mankind & Dr. Reddy's | WTF is Pharma?

I got two of the biggest names in Indian pharma into one room, Rajeev Juneja of Mankind and GV Prasad of Dr. Reddy's, who'd somehow never actually met before this, and what came out was part masterclass and part origin story, from why being relentlessly contrarian beat following the herd, to how a college dropout from Meerut turned everything he hated about a medical store into a pharma giant, to why a chemical engineer who says he owes his career to his marriage spent decades chasing one original molecule, and somewhere in between we got into why India makes the world's generics instead of discovering its own drugs, what it really takes in time and money to bring a single drug to market, why GV thinks the AI-will-cure-everything story is overstated, where GLP-1s go next, and the one thing they'd tell a 25-year-old trying to build in pharma. #nikhilkamath Co-founder of Zerodha and Gruhas Host of 'WTF is' & 'People By WTF' Podcast Twitter: https://x.com/nikhilkamathcio/ Instagram:   / nikhilkamathcio   LinkedIn: https://www.linkedin.com/in/nikhilkam... Facebook:   / nikhilkamathcio   Rajeev Juneja-Vice Chairman & Managing Director at Mankind Pharma Ltd LinkedIN-   / rajeev-juneja-27882a24b   G.V Prasad Reddy-MD & Co-Chairman at Dr. Reddy's Linkedin-  / gvprasadster   Watch 'WTF is' Podcast on Spotify https://tinyurl.com/4nsm4ezn Watch 'People by WTF' Podcast on Spotify https://tinyurl.com/yme92c59 Watch 'WTF Online' on Spotify https://tinyurl.com/4tjua4th 00:00 Introduction 04:27 Rajeev Juneja's path from medical-store apprentice to building Mankind 10:11 Mankind's contrarian OTC and bottom-up market strategy 16:23 G.V. Prasad on science and the Dr. Reddy's lineage 23:06 Segmenting the industry and how generic drugs are made 29:15 Why drug purity standards are shared but enforcement differs 36:40 Why India is the pharmacy of the world by volume, not revenue 41:00 How margins are split across the pharma value chain 45:17 Whether online pharmacy and consumer brands are real openings 53:15 Whether hospital roll-up valuations are justified 59:10 Tariffs, Jan Aushadhi and drug price controls 1:03:21 How China built a pharma-innovation ecosystem in a decade 1:10:02 Long-horizon governance and removing entrepreneurial fear 1:15:40 China's incentives, talent and leverage over the US 1:22:01 Why the Ayush and wellness market outgrows pharma 1:25:05 The evidence, quality and standardisation debate around Ayurveda 1:35:13 The sexual-wellness opportunity and the stigma problem 1:40:26 The fertility, IVF and egg-freezing opportunity 1:43:45 The API narrative debate and how a drug is synthesised 1:50:54 Biologics, monoclonal antibodies and vaccines explained 1:55:57 Stem cells and peptides, separating therapy from hype 2:00:06 The semaglutide story and how GLP-1 works 2:05:01 Mankind's ethical-selling philosophy on GLP-1 2:08:06 Why India leads in small molecules but lags in biologics 2:15:07 Where a young founder can enter the GLP-1 wave 2:23:38 The yin and yang of innovators and generics 2:29:05 Diagnostics, CDMO and the China-plus-one opportunity 2:37:18 Applying AI to pharma and the expired-medicine problem 2:43:01 Why founders should never copy a set formula 2:45:30 Succession, home diagnostics and the microfluidics frontier #WTFiswithnikhilkamath #PeopleByWTF #WTFOnline